Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 expansion study assessing the recommended phase 2 dose, safety and efficacy of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced solid tumors, including head and neck squamous cell carcinoma

Next Previous
Trial Profile

A phase 1 expansion study assessing the recommended phase 2 dose, safety and efficacy of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced solid tumors, including head and neck squamous cell carcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Petosemtamab (Primary)
  • Indications Head and neck cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 07 Aug 2023 According to a Merus media release, Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma.
  • 28 Feb 2023 According to a Merus media release, enrollment continues in dose expansion phase of this study.
  • 03 Nov 2022 According to a Merus media release, the company plans to provide a clinical update from the trial at a medical conference in the first half of 2023. The planned presentation will provide the opportunity to present a robust update, including approximately 40 patients with head and neck squamous cell carcinoma (HNSCC) with meaningful clinical follow up, and an update on the gastro-esophageal cohort, to inform clinical development strategy and planned regulatory interactions.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top